The Sticky Situation with GLP-1 Medications: To Quit or Not to Quit?
GLP-1 medications like Ozempic and Zepbound have become increasingly popular for treating diabetes and obesity. Despite being designed for lifelong use to manage chronic conditions, a significant number of people who start these treatments end up quitting. But what happens when you quit a GLP-1 medication and then plan to start again?
Adherence Rates are Low
Research indicates that adherence to GLP-1 medications is a major issue. According to Dr. Jaime Almandoz, an obesity medicine specialist at the University of Texas Southwestern Medical Center, fewer than 1 in 4 patients remained on a GLP-1 medication after a year. This low adherence rate raises concerns about the effectiveness of these treatments for chronic conditions.
The Risks of Stopping and Starting
While there isn’t extensive research on the consequences of quitting and restarting GLP-1 medications, it’s generally not recommended. Stopping and starting these medications can lead to fluctuations in blood sugar levels and weight, potentially worsening the underlying condition. Moreover, the long-term effects of repeated cycles of starting and stopping GLP-1 medications are not well understood.
What’s Driving the Trend?
The reasons behind the low adherence rates are complex and multifaceted. Some patients may experience side effects, while others may struggle with the cost or the injection regimen. Additionally, the stigma associated with taking medications for weight loss or diabetes management may also play a role.
So, What’s the Takeaway?
If you’re considering quitting a GLP-1 medication or planning to start again, it’s essential to consult with your healthcare provider. They can help you weigh the benefits and risks of continuing or restarting treatment. As the use of GLP-1 medications continues to grow, it’s crucial to address the challenges of adherence and explore strategies to support patients in managing their chronic conditions effectively.
Will the benefits of GLP-1 medications outweigh the challenges of long-term adherence for patients with chronic conditions?